Preview

Kuban Scientific Medical Bulletin

Advanced search

Amiodarone-Induced Hypothyroidism

https://doi.org/10.25207/1608-6228-2019-26-6-127-134

Abstract

Aim: to present a clinical case of amiodarone-induced hypothyroidism in a patient with paroxysmal atrial fi brillation.

Results. Before taking amiodarone, the patient suffered from subclinical hypothyroidism. The level of thyroid stimulating hormone (TSH) was 6.2 mIU/L, thyroxine (T4) — 9.2 pmol/L. Against the background of taking amiodarone in a maintenance dose of 200 mg per day 5 days a week with a break of 2 days, clinically severe hypothyroidism developed with a TSH level of more than 16 mIU/L. An electrocardiogram (ECG) recorded sinus bradycardia with a heart rate (HR) of 37 beats per minute. Paroxysms of atrial fi brillation have stopped. According to the daily ECG monitoring recorded throughout the sinus rhythm with maximum heart rate of 92 beats/min., minimum of 35 beats/min. The circadian rhythm profi le was correct. No pauses were detected for more than two seconds. Transient atrioventricular block was of 1 degree (during sleep). Ectopic activity was represented by supraventricular extrasystoles 112 per day: 107 single, 1 pair, 1 group. Ventricular extrasystoles: 55 per day: polymorphic, solitary. No diagnostically signifi cant elevation or depression of the ST segment was detected. After the abolition of amiodarone, thyroid function was recovered. Levothyroxine was not prescribed. However, paroxysms of atrial fi brillation began to occur again. For the prevention of paroxysms, sotalol 160 mg per day was prescribed.

Conclusion. Thus, the development of clinically pronounced amiodarone-induced hypothyroidism has contributed to the existing thyroid dysfunction in the patient. The assessment of the thyroid gland function and its further monitoring in the process of taking the drug is prescribed. Amiodarone therapy is performed in case of ineffectiveness of other antiarrhythmic drugs and, as a rule, is not used for primary prescription.

About the Authors

Svetlana A. Chepurnenko
Rostov State Medical University; Rostov Regional Hospital
Russian Federation

Svetlana A. Chepurnenko — Dr. Sci. (Med.), Assoc. Prof., Department of General Medical Practice (Family Medicine) with Courses of Geriatrics and Physiotherapy, Faculty of Advanced Training and Retraining; Cardiologist Doctor,  Cardiologic Healthcare Department

Nakhichevan lane, 29, Rostov-on-Don, 344022
Blagodatnaya str., 170, Rostov-on-Don, 344015



Galina V. Shavkuta
Rostov State Medical University
Russian Federation

Galina V. Shavkuta — Dr. Sci. (Med.), Prof., Departmental Head, Department of General Medical Practice (Family Medicine) with Courses of Geriatrics and Physiotherapy

Nakhichevan lane, 29, Rostov-on-Don, 344022



Alina D. Nasytko
Rostov State Medical University
Russian Federation

Alina D. Nasytko — Laboratory Assistant, Departmental Head, Department of General Medical Practice (Family Medicine) with Courses of Geriatrics and Physiotherapy, Faculty of Advanced Training and Retraining

Nakhichevan lane, 29, Rostov-on-Don, 344022



References

1. Wiersinga W.M. Adult hypothyroidism. In: Feingold K.R., Anawalt B., Boyce A., Chrousos G., Dungan K., Grossman A., Hershman J.M., Kaltsas G., Koch C., Kopp P., Korbonits M., McLachlan R., Morley J.E., New M., Perreault L., Purnell J., Rebar R., Singer F., Trence D.L., Vinik A., Wilson D.P., editors. Source Endotext. South Dartmouth (MA): MDText. com, Inc.; 2000–2014.

2. Capel I., Tasa-Vinyals E. Takotsubo cardiomyopathy in amiodarone-induced hyperthyroidism in endocrinology. Endocrinol. Diabetes Metab. Case Rep. 2017; 2017: P. 16–0116. DOI: https://doi.org/10.1530/EDM16-0116

3. Leo S.D., Braverman L.E. Amiodarone-Induced Thyroid Dysfunction: A Comprehensive Guide for the Clinician. In: Luster М., Duntas L., Wartofsky L., editors. The Thyroid and Its Diseases. Springer International Publishing; 2019. 417–433. DОI: 10.1007/978-3-319-72102-6

4. Pino J.D., Diaz M.J., Frejo M.T., editors. Thyroid Toxicity. Bentham Science Publisher; Sharjah, UAE: 2016. P. 97–121. DOI: 10.2174/97816810822191160101

5. Finsterer J., Zarrouk-Mahjoub S. Mitochondrial toxicity of cardiac drugs and its relevance to mitochondrial disorders. Expert. Opin. Drug. Metab. Toxicol. 2015; 11(1): 15–24. DOI: 10.1517/17425255.2015.973401

6. Klein I., Danzi S. Thyroid disease and the heart. Curr. Probl. Cardiol. 2016; 41(2): 65–92. DOI: 10.1016/j.cpcardiol.2015.04.002

7. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., Castella M., Diener H.-Ch., Heidbuchel Н., Hendriks J., Hindricks G., Manolis A. S., Oldgren J., Popescu B. A., Schotten U., Van Putte B., Vardas P. Endorsed by the European Stroke Organisation. 2016 ESC guidelines for the management of atrial fi brillation developed in collaboration with eacts. Eur. Heart J. 2016; 37(38): 2893–2962. DOI: 10.1093/eurheartj/ehw210


Review

For citations:


Chepurnenko S.A., Shavkuta G.V., Nasytko A.D. Amiodarone-Induced Hypothyroidism. Kuban Scientific Medical Bulletin. 2019;26(6):127-134. (In Russ.) https://doi.org/10.25207/1608-6228-2019-26-6-127-134

Views: 2097


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1608-6228 (Print)
ISSN 2541-9544 (Online)